Euphoriants

Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

Entheogens, Euphoriants, Medicinal plants, Cannabis, Cannabis smoking, Clever, Plants, University of California, Davis, Psychoactive drugs, Geography of California
Tuesday, July 27, 2021 - 1:00pm

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S., today announced a joint partnership with the intent to study the DNA sequence variation of three Clever Leaves’ cannabis cultivars as part of their Project Change Lives campaign. The University of California, Davis (“UC Davis”), through an accepted research sponsorship from BRC, will lead the extraction and analysis of DNA to elucidate genetic variants taken from various genetic lines of Cannabis sativa.

Key Points: 
  • The initiative is part of Project Change Lives; Clever Leaves $25M product pledge to aid cannabis research in the U.S.
  • UC Davis will be the first major research institution to collaborate in the investigation of Clever Leaves Colombian and Portuguese, pharmaceutical-grade cannabis as part of Project Change Lives.
  • We are honored to collaborate with the UC Davis Plant Science department, said Kyle Detwiler, CEO of Clever Leaves.
  • To eliminate an additional impediment to the advancement of scientific knowledge around cannabis, this research material will be provided at no cost to Clever Leaves research partners.

Flor Americas Partners with Biosintex Laboratorios to Supply Cannabinoids for Argentina’s Pharmaceutical Market

Biotechnology, Alternative medicine, Health, Pharmaceutical, Medical Supplies, Cannabis, Cannabis smoking, Entheogens, Euphoriants, Legality of cannabis, Psychoactive drugs, Medical specialties
Tuesday, July 27, 2021 - 12:17pm

Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.

Key Points: 
  • Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.
  • During the past 20 years, Biosintex Laboratorios has earned a reputation for developing and manufacturing world-class pharmaceuticals.
  • Recently, Biosintex Laboratorios received authorization to import CBD from a producer within Flor Americas network.
  • Biosintex Laboratorios is an Argentine pharmaceutical company that develops and manufactures medicinal products with more than 20 years of experience in the market.

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

Drugs, Health care, Health sciences, Morphinans, Euphoriants, Drug culture, Oxycodone, Clinical research, Design of experiments, Clinical trial, Medroxyprogesterone acetate
Tuesday, July 27, 2021 - 12:35pm

The study comparing REL-1017 to oxycodone is the first of two clinical trials to assess abuse potential per FDA guidance as part of the planned REL-1017 NDA for the treatment of MDD.

Key Points: 
  • The study comparing REL-1017 to oxycodone is the first of two clinical trials to assess abuse potential per FDA guidance as part of the planned REL-1017 NDA for the treatment of MDD.
  • The scheduling of a drug depends on the analysis of several parameters (receptor studies, animal studies, human studies, history of abuse).
  • Oxycodone, the active control, was administered at the dose of 40 mg, a standard dose in HAP studies.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

BC Craft Supply Co Debuts Grizzlers Brand in Alberta Through Revolutionary $1 “Buck a Joint” S^MPLE by AHLOT™ Program.

Entheogens, Psychoactive drugs, Cannabis smoking, Euphoriants, Medicinal plants, Drug culture, Cannabis culture, Cannabis, Effects of cannabis
Tuesday, July 27, 2021 - 12:00pm

The S^MPLE by AHLOT program brings traditional CPG sampling to the cannabis industry, in a compliant manner.

Key Points: 
  • The S^MPLE by AHLOT program brings traditional CPG sampling to the cannabis industry, in a compliant manner.
  • BC Craft Supply Co Ltd is a diversified wellness company advancing cannabinoid and psychedelic innovation and psychotherapy.
  • BC Craft works with local artists cross-sector and remains fervently committed to keeping the art, technique, and purity of their pursuit.
  • For AHLOT media information:
    THE CANADIAN SECURITIES EXCHANGE (THE CSE) HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE.

Global Medical Marijuana Market to 2027 - ResearchAndMarkets.com

Health, Pharmaceutical, Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Cannabis, Entheogens, Euphoriants, Medical cannabis
Tuesday, July 27, 2021 - 11:15am

The "Global Medical Marijuana Market to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Marijuana Market to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Increase in awareness regarding various medical applications such as appetite enhancement, pain management, and reducing eye pressure is the key driving factor which is expected to boost the global medical marijuana market growth.
  • However, Medical marijuana is not approved by USFDA (Food and Drug Administration) for the treatment of cancer which is major restraining factor which is expected to hamper the global medical marijuana market growth.
  • Global Medical Marijuana Market is segmented into route of administration such as Oral, Inhalation, and Topical.

Curaleaf International Launches Second Medical Cannabis Flower Product for UK Market

Alternative medicine, Health, Science, Pharmaceutical, Research, Medicinal plants, Psychoactive drugs, Health sciences, Herbalism, Cannabis smoking, Entheogens, Euphoriants, Branches of biology, Curaleaf, Cannabis, Medical cannabis, Effects of cannabis
Tuesday, July 27, 2021 - 7:00am

Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.

Key Points: 
  • Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.
  • The new products are being manufactured in the UK and will be an extension to Curaleaf Internationals existing range of medical cannabis flower and oil products.
  • Antonio Costanzo, CEO of Curaleaf International, commented: We are very pleased to extend our range of medical cannabis products for the UK market.
  • As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products.

Psyched Wellness Enters into a Service Agreement with CannaLabs to Begin Stability Tests on AME-1

Cannabis, Cannabis smoking, Entheogens, Euphoriants, Agilent Technologies, Health Canada, Dietary supplement, Companies, Medicine, Health care
Monday, July 26, 2021 - 12:30pm

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Key Points: 
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
  • The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
  • CannaLabs Science Inc. is a Canadian-based, Health Canada licensed analytical laboratory.
  • The Company's state of the art lab specializes in analytical testing for the cannabis, natural health products and pharmaceutical industries.

Endexx Corporation and DJ Khaled’s BLESSWELL Shows Strong Promise in the CBD Wellness Sector Within First Months of Debut

Entheogens, Euphoriants, Psychoactive drugs, Medicinal plants, Branches of biology, Drugs, Herbs, Herbalism, Cannabis sativa, Cannabis, Hemp, Medical cannabis
Tuesday, July 27, 2021 - 1:00am

Cave Creek, AZ, July 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- In May of 2021, Endexx Corporation (OTC: EDXC), the leading producer and manufacturer of hemp-derived CBD wellness products, and legendary music artist DJ Khaled, officially joined forces to launch BLESSWELL™. The clean and natural CBD-infused men’s grooming line is designed to be an essential toolkit for a man's complete at-home self-care needs. 

Key Points: 
  • The clean and natural CBD-infused mens grooming line is designed to be an essential toolkit for a man's complete at-home self-care needs.
  • Taking place in early June, BLESSWELL partnered with iconic fashion brand, Von Dutch, to host a Summer Fridays Kickoff event in Hollywood, CA.
  • Celebrities, influencers, and media such as Terrence J., Sarunas J. Jackson, Rolling Stone, and Hypebeast attended the exclusive summer soiree.
  • Endexx Corporation, through its operating division CBD Unlimited, develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC.

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

Acura Pharmaceuticals, Euphoriants, Morphinans, Health care, Pharmaceuticals policy, Ketones, LTX, Acura, Hydromorphone, Pharmaceutical industry in China, Psychoactive drugs, Health
Monday, July 26, 2021 - 9:15pm

PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharma, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to February 28, 2022.

Key Points: 
  • PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharma, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to February 28, 2022.
  • Clinical studies with hydromorphone (LTX-04) demonstrated reductions in Cmax of up to 65% when up to 8 tablets were ingested.
  • Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse.
  • LIMITx is useful with products whose side effect risks can be mitigated by limiting exposure to a drug in overdose situations.

Allied Corp Commends the Colombian Authorities for Approving the Export of Dried Cannabis Flower From Colombia

Entheogens, Euphoriants, Medicinal plants, Articles, Drug control law, Countries, Psychoactive drugs, Cannabis, Cannabis smoking, Colombia, Duque, Iván Duque Márquez
Monday, July 26, 2021 - 1:55pm

On July 23, 2021 the President of Colombia, President Ivan Duque, signed a decree lifting a prohibition on exporting dried cannabis flower.

Key Points: 
  • On July 23, 2021 the President of Colombia, President Ivan Duque, signed a decree lifting a prohibition on exporting dried cannabis flower.
  • While only a few Colombian companies have been able to export cannabis derivatives such as CBD distillate and isolate, up until now, the export of dried flower from Colombia has been prohibited.
  • "This means Colombia can enter to play a big role in the international market," Duque said after signing the decree.
  • We are proud to bring to market the Colombian flower that Allied has produced, said Calum Hughes, CEO of Allied.